TABLE 3 AEs in the safety analysis set AEs, n (%) Exenatide QW + IG (n = 232) Placebo + IG (n = 231) Any AE 125 (53.9) 133 (57.6) Any SAE 11 (4.7) 11 (4.8)AEs leading to study withdrawal 7 (3.0) 5 (2.2) SAEs leading to study withdrawal 1 (0.4) 1 (0.4) Deaths 0 (0.0) 1 (0.4)AEs occurring in ≥5% of patients in either treatment group Urinary tract infection 18 (7.8) 15 (6.5) Nausea 12 (5.2) 9 (3.9)Increased blood creatine phosphokinase 5 (2.2) 13 (5.6) Injection-site nodule 12 (5.2) 1 (0.4) AEs of special interest Hypoglycaemia a Major 0 (0.0) 0 (0.0) Minor 13 (5.6) 13 (5.6) Other 68 (29.3) 64 (27.7) Confirmed, adjudicated cardiovascular events 0 (0.0) 3 (1.3) Pancreatitis 1 (0.4) 0 (0.0) Acute renal failure-related 1 (0.4) 0 (0.0)Neoplasm-related 4 (1.7) 2 (0.9) Seborrheic keratosis 2 (0.9) 0 (0.0) Adrenal adenoma 0 (0.0) 1 (0.4)Angiomyolipoma 1 (0.4) 0 (0.0) Benign oesophageal neoplasm 0 (0.0) 1 (0.4) Squamous cell carcinoma 1 (0.4) 0 (0.0) Injection-site –related 18 (7.8) 7 (3.0)